ArticleCureus2025
Clinical Implications of Mechanical and Adhesive Differences Between Branded and Generic Tulobuterol Patches in Asthma Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study This study aimed to evaluate the mechanical and adhesive properties of one branded and six generic tulobuterol transdermal patches commonly used for asthma treatment in Japan, and to clarify how differences in excipient composition influence patch usability and performance. Materials and methods A branded tulobuterol patch and six generic alternatives were analyzed. Mechanical strength was assessed using a uniaxial tensile tester, and adhesive performance (tackiness) was evaluated with a spherical probe detachment test. All measurements were conducted in quintuplicate under controlled temperature (25 ± 2°C) and humidity (60 ± 5% RH). Excipient compositions were identified from publicly available package inserts. Results Significant formulation-dependent differences were observed. The branded patch ruptured early under high stress with limited elongation, indicating rigidity, whereas several generics exhibited higher flexibility and elongation before rupture. Tackiness values also varied widely: some generics showed excessive adhesion, while others exhibited insufficient tackiness. These variations correlated strongly with differences in adhesive polymers and plasticizers. Conclusion Despite having equivalent pharmacokinetic profiles, branded and generic tulobuterol patches differ in their mechanical and adhesive characteristics, which may influence clinical usability and patient adherence. The results emphasize the importance of considering excipient-driven performance when selecting transdermal products for asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.